{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:35:15Z","timestamp":1791459315595,"version":"4.3.4"},"reference-count":201,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Facultad de Ciencias M\u00e9dicas","award":["2-03-01-01"],"award-info":[{"award-number":["2-03-01-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Yellow fever, a mosquito-borne viral hemorrhagic disease, remains a significant public health concern in endemic regions of Africa and South America. The development of the yellow fever vaccine marked a milestone in virology and immunization. In the 1930s, Max Theiler created the 17D live-attenuated vaccine, a breakthrough that has achieved global recognition and continues to underpin prevention strategies. This review outlines the historical evolution of the yellow fever vaccine, highlighting pivotal scientific advances, technological innovations, and global eradication initiatives. It examines the current landscape of immunization, focusing on the World Health Organization\u2019s Eliminate Yellow Fever Epidemics (EYE) strategy, ongoing efforts to address vaccine supply constraints, and persistent surveillance gaps. Future directions in vaccine development, including next-generation platforms and improved delivery systems, are also discussed, alongside the need for sustained research investment and international collaboration. As yellow fever emerges in previously non-endemic areas due to climate change and globalization, strengthening vaccination programs remains critical to preventing outbreaks and ensuring effective disease control.<\/jats:p>","DOI":"10.3390\/vaccines14010065","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:28:57Z","timestamp":1767626937000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Yellow Fever Vaccine Journey: Milestones and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-4381","authenticated-orcid":false,"given":"Shriyansh","family":"Srivastava","sequence":"first","affiliation":[{"name":"School of Medical and Allied Sciences, Galgotias University, Greater Noida 203201, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7921-9948","authenticated-orcid":false,"given":"Nandani","family":"Jayaswal","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Mahayogi Gorakhnath University Gorakhpur, Gorakhpur 273007, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Gupta","sequence":"additional","affiliation":[{"name":"School of Medical and Allied Sciences, Galgotias University, Greater Noida 203201, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik Belagodu","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK, Medical and Health Sciences University, Ras Al Khaimah 71705, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Mahayogi Gorakhnath University Gorakhpur, Gorakhpur 273007, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-4512","authenticated-orcid":false,"given":"Mohd.","family":"Tariq","sequence":"additional","affiliation":[{"name":"Department of Academics, Sumandeep Vidyapeeth (Deemed to be University), Vadodara 391760, Gujarat, India"},{"name":"Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun 248002, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S. N. Koteswara","family":"Rao","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM\u2019s NMIMS, Mumbai 400056, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-5014","authenticated-orcid":false,"given":"Aroop","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Microbiology, AIIMS Gorakhpur, Gorakhpur 273008, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit","family":"Sah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Dr. D.Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune 411018, Maharashtra, India"},{"name":"Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune 411018, Maharashtra, India"},{"name":"Department of Medicine, Korea University, Seoul 02481, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Mehta","sequence":"additional","affiliation":[{"name":"Dr. Lal PathLabs Nepal, Chandol, Kathmandu 44600, Nepal"},{"name":"Clinical Microbiology, RDC, Manav Rachna International Institute of Research and Studies, Faridabad 121004, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Hern\u00e1ndez-Ovalle","sequence":"additional","affiliation":[{"name":"Program of Family Medicine Specialization, Faculty of Medicine, Fundaci\u00f3n Universitaria Aut\u00f3noma de las Am\u00e9ricas-Instituci\u00f3n Universitaria Visi\u00f3n de las Am\u00e9ricas, Pereira 660007, Risaralda, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-2732","authenticated-orcid":false,"given":"Jaime D.","family":"Acosta-Espa\u00f1a","sequence":"additional","affiliation":[{"name":"Health Sciences Faculty, Universidad Internacional SEK (UISEK), Quito 170120, Ecuador"},{"name":"School of Medicine, Pontificia Universidad Cat\u00f3lica del Ecuador, Quito 170120, Ecuador"},{"name":"Institute of Microbiology, Friedrich Schiller University Jena, 07737 Jena, Germany"},{"name":"Research Group of Emerging and Neglected Diseases, Ecoepidemiology and Biodiversity, Health Sciences Faculty, Universidad Internacional SEK (UISEK), Quito 170120, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5807","authenticated-orcid":false,"given":"Lysien","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Department of Morphological Sciences, School of Medical Sciences, Universidad Nacional Aut\u00f3noma de Honduras, Tegucigalpa 11101, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9773-2192","authenticated-orcid":false,"given":"Alfonso J.","family":"Rodriguez-Morales","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Universidad Cient\u00edfica del Sur, Lima 15067, Peru"},{"name":"Grupo de Investigaci\u00f3n Biomedicina, Faculty of Medicine, Fundaci\u00f3n Universitaria Aut\u00f3noma de las Am\u00e9ricas-Instituci\u00f3n Universitaria Visi\u00f3n de las Am\u00e9ricas, Pereira 660003, Risaralda, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.nmni.2025.101580","article-title":"Yellow fever outbreaks in South America: Current epidemiology, legacies of the recent past and perspectives for the near future","volume":"65","author":"Angerami","year":"2025","journal-title":"New Microbes New Infect."},{"key":"ref_2","first-page":"434","article-title":"Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches","volume":"32","author":"Srivastava","year":"2024","journal-title":"Infez. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S1473-3099(20)30170-5","article-title":"Prevention of yellow fever in travellers: An update","volume":"20","author":"Reno","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bassey, B.E., Braka, F., Onyibe, R., Kolude, O.O., Oluwadare, M., Oluwabukola, A., Omotunde, O., Iyanda, O.A., Tella, A.A., and Olanike, O.S. (2022). Changing epidemiology of yellow fever virus in Oyo State, Nigeria. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-12871-0"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(19)30125-2","article-title":"Predictors of mortality in patients with yellow fever: An observational cohort study","volume":"19","author":"Kallas","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","first-page":"673","article-title":"Yellow fever in eighteenth century America","volume":"44","author":"Blake","year":"1968","journal-title":"Bull. N. Y. Acad. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.ento.52.110405.091454","article-title":"Yellow fever: A disease that has yet to be conquered","volume":"52","author":"Barrett","year":"2007","journal-title":"Annu. Rev. Entomol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alshahrani, N.Z., Algethami, M.R., Albeshry, A.M., Awan, Z., Alzhrani, W., Fairaq, B.A., and Rashid, H. (2025). Respiratory symptom burden, vaccination coverage, and preventive health practices among Sudanese Hajj pilgrims who traveled by sea. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1702386"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.2147\/DDDT.S99600","article-title":"Yellow fever vaccine-associated viscerotropic disease: Current perspectives","volume":"10","author":"Thomas","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_10","unstructured":"Petersen, J.L. (1977). Behavioral Differences in Two Subspecies of Aedes aegypti (L.) (Diptera: Culicidae) in East Africa. [Ph.D. Thesis, University of Notre Dame]."},{"key":"ref_11","first-page":"2216","article-title":"Reemergence of Yellow Fever, Magdalena Valley, Colombia, 2024\u20132025","volume":"31","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sanchez-Rojas, I.C., Bonilla-Aldana, D.K., Solarte-Jimenez, C.L., Bonilla-Aldana, J.L., Belisario-Tovar, M., Ortega-G\u00f3mez, S., Zambrano-Quenan, V.M., Perafan-Gomez, J.C., Gomez-Ocampo, C.H., and Delgado-Cajigas, M. (2025). Fatal yellow fever among captive non-human primates in southern Colombia, 2025. Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1655474"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s40475-025-00349-z","article-title":"Importance of Epizootic Surveillance in the Epidemiology of Yellow Fever in South America","volume":"12","author":"Castellanos","year":"2025","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Escalera-Antezana, J.P., Aviles-Sarmiento, J.L., Montenegro-Narvaez, C.M., Castro-Calderon, H.A., Bonilla-Aldana, J.L., Bonilla-Aldana, D.K., and Rodriguez-Morales, A.J. (2025). Yellow Fever among Captive Non-Human Primates in La Paz, Bolivia, 2025. New Microbes New Infect., 101695.","DOI":"10.1016\/j.nmni.2025.101695"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101572","DOI":"10.1016\/j.nmni.2025.101572","article-title":"Yellow fever in Putumayo, Colombia, 2024","volume":"64","author":"Arevalo","year":"2025","journal-title":"New Microbes New Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trstmh.2006.04.001","article-title":"Clinical and epidemiological characteristics of yellow fever in Brazil: Analysis of reported cases 1998\u20132002","volume":"101","author":"Tuboi","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S1473-3099(17)30419-X","article-title":"Global yellow fever vaccination coverage from 1970 to 2016: An adjusted retrospective analysis","volume":"17","author":"Shearer","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","first-page":"77","article-title":"The yellow fever vaccine: A history","volume":"83","author":"Frierson","year":"2010","journal-title":"Yale J. Biol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref_21","first-page":"101144","article-title":"Colombian consensus on the care of critically ill patients with suspected or confirmed severe yellow fever","volume":"48","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever\u2014Challenges for the development and use of vaccines","volume":"357","author":"Monath","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014How does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bassi, M.R., Larsen, M.A., Kongsgaard, M., Rasmussen, M., Buus, S., Stryhn, A., Thomsen, A.R., and Christensen, J.P. (2016). Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004464"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4049\/jimmunol.2001381","article-title":"Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination","volume":"207","author":"Sandberg","year":"2021","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., and Grobusch, M.P. (2016). A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149871"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.tmaid.2025.102871","article-title":"Yellow fever in South America\u2014A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN","volume":"67","author":"Alhazmi","year":"2025","journal-title":"Travel. Med. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127851","DOI":"10.1016\/j.vaccine.2025.127851","article-title":"TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets","volume":"66","author":"Iversen","year":"2025","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Strother, A.E., Thompson, J.K., Widen, S.G., and Barrett, A.D.T. (2022). Genetic Diversity Does Not Contribute to Attenuation of HeLa Passaged Wild-Type Yellow Fever Virus Strain French Viscerotropic Virus. Viruses, 14.","DOI":"10.3390\/v14030527"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0264-410X(01)00439-X","article-title":"Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing","volume":"20","author":"Pugachev","year":"2002","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"198935","DOI":"10.1016\/j.virusres.2022.198935","article-title":"Establishment of Vero cell lines persistently harboring a yellow fever virus 17D subgenomic replicon","volume":"322","author":"Saito","year":"2022","journal-title":"Virus Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.vaccine.2014.02.036","article-title":"Development of a membrane adsorber based capture step for the purification of yellow fever virus","volume":"32","author":"Pato","year":"2014","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hong, Q., Liu, J., Wei, Y., and Wei, X. (2023). Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development. Vaccines, 11.","DOI":"10.3390\/vaccines11071218"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.vaccine.2012.01.016","article-title":"Recombinant protein vaccines produced in insect cells","volume":"30","author":"Cox","year":"2012","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: Challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2599628","DOI":"10.1080\/21645515.2025.2599628","article-title":"Strategic positioning of immunization at the heart of Africa\u2019s health and development agenda","volume":"21","author":"Wiysonge","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rodriguez-Morales, A.J., Sah, R., Silva-Ramos, C.R., and Pava-Garz\u00f3n, D.M. (2025). Challenges in Emerging and Reemerging Arboviral Diseases: The Examples of Oropouche and Yellow Fever. Pathogens, 14.","DOI":"10.3390\/pathogens14070621"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"D74","DOI":"10.1016\/j.vaccine.2012.01.080","article-title":"The expanded programme on immunization: A lasting legacy of smallpox eradication","volume":"29","author":"Cherian","year":"2011","journal-title":"Vaccine"},{"key":"ref_39","first-page":"1","article-title":"Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002","volume":"51","author":"Cetron","year":"2002","journal-title":"Morb. Mortal. Wkly. Rep. Recomm. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mokaya, J., Kimathi, D., Lambe, T., and Warimwe, G.M. (2021). What Constitutes Protective Immunity Following Yellow Fever Vaccination?. Vaccines, 9.","DOI":"10.3390\/vaccines9060671"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e02494-19","DOI":"10.1128\/mBio.02494-19","article-title":"A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies","volume":"11","author":"Mishra","year":"2020","journal-title":"mBio"},{"key":"ref_43","first-page":"115330","article-title":"Targeting Yellow-Fever Virus: Development of a specific aptamer to NS1 protein","volume":"341","author":"Miranda","year":"2025","journal-title":"J. Virol. Methods"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mateus, J., Grifoni, A., Voic, H., Angelo, M.A., Phillips, E., Mallal, S., Sidney, J., Sette, A., and Weiskopf, D. (2020). Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. Viruses, 12.","DOI":"10.3390\/v12111300"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00430-021-00700-x","article-title":"Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine","volume":"210","author":"Lim","year":"2021","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1038\/s41598-024-60680-9","article-title":"Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development","volume":"14","author":"Manzoni","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Roy, R.R., Tadkalkar, N., Deshpande, G.R., Atre, N.M., Shil, P., and Sapkal, G. (2025). Identification of B-cell epitopes of Indian Zika virus strains using immunoinformatics. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1534737"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Iyyanar, S., and Ravi, S.N. (2025). Vaccine Development T-cell (MHC-I) Epitopes Identification Against the Indian HCV Genotype: An Approach Based on Immunoinformatic. Mol. Biotechnol.","DOI":"10.1007\/s12033-025-01398-5"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e0051222","DOI":"10.1128\/mbio.00512-22","article-title":"Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus","volume":"13","author":"Doyle","year":"2022","journal-title":"mBio"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0177024","DOI":"10.1128\/jvi.01770-24","article-title":"A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity","volume":"99","author":"Lou","year":"2025","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coi.2019.03.003","article-title":"Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines","volume":"59","author":"Xu","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bj.2020.01.002","article-title":"Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus","volume":"44","author":"Olotu","year":"2021","journal-title":"Biomed. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100194","DOI":"10.1016\/j.xcrm.2021.100194","article-title":"Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting","volume":"2","author":"Schmidt","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/07391102.2021.2024253","article-title":"Modeling mRNA-based vaccine YFV.E1988 against yellow fever virus E-protein using immuno-informatics and reverse vaccinology approach","volume":"41","author":"Khan","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1080\/07391102.2019.1651673","article-title":"In silico analysis for development of epitopes-based peptide vaccine against Alkhurma hemorrhagic fever virus","volume":"38","author":"Shabbir","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.vaccine.2010.08.046","article-title":"Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults","volume":"29","author":"Silva","year":"2011","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Campi-Azevedo, A.C., de Araujo-Porto, L.P., Luiza-Silva, M., Batista, M.A., Martins, M.A., Sathler-Avelar, R., da Silveira-Lemos, D., Camacho, L.A., de Menezes Martins, R., and de Lourdes de Sousa Maia, M. (2012). 17DD and 17D-213\/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049828"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/eji.201142306","article-title":"The early cellular signatures of protective immunity induced by live viral vaccination","volume":"42","author":"Kohler","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jir439","article-title":"Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody","volume":"204","author":"Batista","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14760584.2018.1406800","article-title":"The 17D-204 and 17DD yellow fever vaccines: An overview of major similarities and subtle differences","volume":"17","author":"Ferreira","year":"2018","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.4049\/jimmunol.1700083","article-title":"A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine","volume":"199","author":"Hou","year":"2017","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2021.12.029","article-title":"Exploratory study of humoral and cellular immunity to 17DD yellow fever vaccination in children and adults residents of areas without circulation of yellow fever virus","volume":"40","author":"Reis","year":"2022","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-019-1854-6","article-title":"Collaborative Group for Studies of Yellow Fever Vaccine Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis","volume":"21","author":"Ferreira","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jinf.2016.02.017","article-title":"17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients","volume":"72","author":"Wieten","year":"2016","journal-title":"J. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J. Med. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00819-17","DOI":"10.1128\/mBio.00819-17","article-title":"Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo","volume":"8","author":"Douam","year":"2017","journal-title":"mBio"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41541-017-0039-z","article-title":"Gamma-interferon exerts a critical early restriction on replication and dissemination of yellow fever virus vaccine strain 17D-204","volume":"3","author":"Lam","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"tay108","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J. Travel. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Stryhn, A., Kongsgaard, M., Rasmussen, M., Harndahl, M.N., Osterbye, T., Bassi, M.R., Thybo, S., Gabriel, M., Hansen, M.B., and Nielsen, M. (2020). A Systematic, Unbiased Mapping of CD8(+) and CD4(+) T Cell Epitopes in Yellow Fever Vaccinees. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01836"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12794","DOI":"10.1128\/JVI.01160-13","article-title":"Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins","volume":"87","author":"James","year":"2013","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Maciel, M., Cruz Fda, S., Cordeiro, M.T., da Motta, M.A., Cassemiro, K.M., Maia Rde, C., de Figueiredo, R.C., Galler, R., Freire Mda, S., and August, J.T. (2015). A DNA vaccine against yellow fever virus: Development and evaluation. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003693"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-008-9267-3","article-title":"Human immune memory to yellow fever and smallpox vaccination","volume":"29","author":"Wrammert","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2010.155","article-title":"Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines","volume":"89","author":"Ahmed","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.vaccine.2022.11.051","article-title":"Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques","volume":"41","author":"Broudic","year":"2023","journal-title":"Vaccine"},{"key":"ref_81","first-page":"282ra48","article-title":"Long-lasting stem cell\u2013like memory CD8+ T cells with a na\u00efve-like profile upon yellow fever vaccination","volume":"7","author":"Soneson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/cid\/ciac580","article-title":"Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis","volume":"75","author":"Kling","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1016\/j.vaccine.2019.05.048","article-title":"Duration of immunity in recipients of two doses of 17DD yellow fever vaccine","volume":"37","author":"Vaccines","year":"2019","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Collaborative Group for Studies on Yellow Fever Vaccines (2014). Duration of post-vaccination immunity against yellow fever in adults. Vaccine, 32, 4977\u20134984.","DOI":"10.1016\/j.vaccine.2014.07.021"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"taac095","DOI":"10.1093\/jtm\/taac095","article-title":"Yellow fever vaccine safety in immunocompromised individuals: A systematic review and meta-analysis","volume":"30","author":"Caetano","year":"2023","journal-title":"J. Travel. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1016\/j.vaccine.2020.08.020","article-title":"Safety of yellow fever vaccine administration in confirmed egg-allergic patients","volume":"38","author":"Gerhardt","year":"2020","journal-title":"Vaccine"},{"key":"ref_87","first-page":"52","article-title":"No Yellow Fever Vaccine Reactions in IgE-Mediated Egg Allergic Patients","volume":"186","author":"Calle","year":"2025","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/INF.0000000000002625","article-title":"Yellow Fever Vaccination In EGG-Allergic Children","volume":"39","author":"Sharma","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"taad037","DOI":"10.1093\/jtm\/taad037","article-title":"Enhanced safety surveillance of STAMARIL\u00ae yellow fever vaccine provided under the expanded access investigational new drug program in the USA","volume":"30","author":"Rojas","year":"2023","journal-title":"J. Travel. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ACI.0000000000000933","article-title":"Epidemiology of anaphylaxis: Is the trend still going up?","volume":"23","author":"Tanno","year":"2023","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u20132013","volume":"23","author":"Lindsey","year":"2016","journal-title":"J. Travel. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1080\/21645515.2015.1022700","article-title":"Serious adverse events associated with yellow fever vaccine","volume":"11","author":"Homma","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/157488611797579258","article-title":"Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: Systematic review","volume":"6","author":"Thomas","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","article-title":"Anaphylaxis from yellow fever vaccine","volume":"103","author":"Kelso","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e96031","DOI":"10.1172\/jci.insight.96031","article-title":"Early molecular correlates of adverse events following yellow fever vaccination","volume":"2","author":"Chan","year":"2017","journal-title":"JCI Insight"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: A report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jtm.12070","article-title":"Safety of the yellow fever vaccine: A retrospective study","volume":"20","author":"Nordin","year":"2013","journal-title":"J. Travel. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.provac.2010.07.012","article-title":"Yellow Fever Vaccine Post-marketing Surveillance in Brazil","volume":"2","author":"Martins","year":"2010","journal-title":"Procedia Vaccinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAXTM and YF-VAX (R)) in healthy infants and","volume":"72","author":"Sanchez","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"de Abreu, A.J.L., Cavalcante, J.R., de Ara\u00fajo Lagos, L.W., Caetano, R., and Braga, J.U. (2022). A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population. Vaccines, 10.","DOI":"10.3390\/vaccines10050711"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"126758","DOI":"10.1016\/j.vaccine.2025.126758","article-title":"Real-world evidence of yellow Fever vaccination data-driven study","volume":"48","author":"Farnsworth","year":"2025","journal-title":"Vaccine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.vaccine.2021.12.047","article-title":"Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases","volume":"40","author":"Ledlie","year":"2022","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/QAI.0000000000000845","article-title":"CD4\/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients","volume":"71","author":"Miyaji","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.vaccine.2020.01.045","article-title":"Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies","volume":"38","author":"Bovay","year":"2020","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-017-00798-1","article-title":"Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination","volume":"7","author":"Kongsgaard","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"taaa172","DOI":"10.1093\/jtm\/taaa172","article-title":"A clinician\u2019s perspective on yellow fever vaccine-associated neurotropic disease","volume":"27","author":"Lecomte","year":"2020","journal-title":"J. Travel. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"de Andrade Gandolfi, F., Estofolete, C.F., Wakai, M.C., Negri, A.F., Barcelos, M.D., Vasilakis, N., and Nogueira, M.L. (2023). Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD. Vaccines, 11.","DOI":"10.3390\/vaccines11020445"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/cid\/ciy777","article-title":"What\u2019s Old Is New Again: The Re-emergence of Yellow Fever in Brazil and Vaccine Shortages","volume":"68","author":"Chen","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1017\/S0950268804002602","article-title":"Risk of fatal adverse events associated with 17DD yellow fever vaccine","volume":"132","author":"Struchiner","year":"2004","journal-title":"Epidemiol. Infect."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"taad160","DOI":"10.1093\/jtm\/taad160","article-title":"Yellow fever vaccine-associated neurologic and viscerotropic disease: A 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights","volume":"31","author":"Durand","year":"2024","journal-title":"J. Travel. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"taw020","DOI":"10.1093\/jtm\/taw020","article-title":"First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong","volume":"23","author":"Leung","year":"2016","journal-title":"J. Travel. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e0224622","DOI":"10.1128\/spectrum.02246-22","article-title":"Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.4269\/ajtmh.21-0235","article-title":"Case Report: Fatal Viscerotropic Disease in a Young Woman Following Yellow Fever Vaccination","volume":"105","author":"Brunaldi","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1590\/s1678-9946202466050","article-title":"Fatal viscerotropic and neurotropic disease after yellow fever vaccine: A rare manifestation leading to diagnosis of severe combined immunodeficiency in an infant","volume":"66","author":"Vieira","year":"2024","journal-title":"Rev. Inst. Med. Trop."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Volkov, L., Grard, G., Bollaert, P.E., Durand, G.A., Cravoisy, A., Conrad, M., Nace, L., Courte, G., Marnai, R., and Leparc-Goffart, I. (2020). Viscerotropic disease and acute uveitis following yellow fever vaccination: A case report. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4838-x"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40409-018-0162-y","article-title":"Yellow fever in Africa and the Americas: A historical and epidemiological perspective","volume":"24","author":"Chippaux","year":"2018","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: Current epidemiology and vaccination strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel. Med. Vaccines"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-4458-4_1","article-title":"Flow Cytometry as Immunoassay Tool for Research on Yellow Fever Virus","volume":"2913","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nomhwange, T., Jean Baptiste, A.E., Ezebilo, O., Oteri, J., Olajide, L., Emelife, K., Hassan, S., Nomhwange, E.R., Adejoh, K., and Ireye, F. (2021). The resurgence of yellow fever outbreaks in Nigeria: A 2-year review 2017\u20132019. BMC Infect Dis, 21.","DOI":"10.1186\/s12879-021-06727-y"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Diagne, M.M., Ndione, M.H.D., Gaye, A., Barry, M.A., Diallo, D., Diallo, A., Mwakibete, L.L., Diop, M., Ndiaye, E.H., and Ahyong, V. (2021). Yellow Fever Outbreak in Eastern Senegal, 2020\u20132021. Viruses, 13.","DOI":"10.3390\/v13081475"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e20201252","DOI":"10.1590\/0001-3765202220201252","article-title":"The second coming of urban yellow fever in the Americas: Looking the past to see the future","volume":"94","author":"Salomon","year":"2022","journal-title":"An. Acad. Bras. Cienc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"101651","DOI":"10.1016\/j.nmni.2025.101651","article-title":"Clinical features of yellow fever in cases from Bolivia, Ecuador, Colombia, and Peru (2023\u20132025): A descriptive retrospective study","volume":"68","author":"Gross","year":"2025","journal-title":"New Microbes New Infect."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhao, S., Stone, L., Gao, D., and He, D. (2018). Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006158"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42522-024-00103-x","article-title":"A proposed One Health approach to control yellow fever outbreaks in Uganda","volume":"6","author":"Mensah","year":"2024","journal-title":"One Health Outlook"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"398","DOI":"10.12688\/f1000research.11280.1","article-title":"Yellow fever in the Americas: The growing concern about new epidemics","volume":"6","year":"2017","journal-title":"F1000Research"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"20418","DOI":"10.1038\/s41598-019-56650-1","article-title":"Origin of the S\u00e3o Paulo Yellow Fever epidemic of 2017\u20132018 revealed through molecular epidemiological analysis of fatal cases","volume":"9","author":"Cunha","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: The recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1126\/science.aat7115","article-title":"Genomic and epidemiological monitoring of yellow fever virus transmission potential","volume":"361","author":"Faria","year":"2018","journal-title":"Science"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/1995-7645.250837","article-title":"Epidemiological, prevention and control updates of yellow fever outbreak in Brazil","volume":"12","author":"Garcia","year":"2019","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015\u201316: A modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s40475-023-00289-6","article-title":"Yellow Fever Reemergence Risk in the Guiana Shield: A Comprehensive Review of Cases Between 1990 and 2022","volume":"10","author":"Thomas","year":"2023","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijid.2016.04.025","article-title":"Yellow fever cases in Asia: Primed for an epidemic","volume":"48","author":"Wasserman","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/infdis\/jiz375","article-title":"Global Risk and Elimination of Yellow Fever Epidemics","volume":"221","author":"Pandey","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Jean, K., Hamlet, A., Benzler, J., Cibrelus, L., Gaythorpe, K.A., Sall, A., Ferguson, N.M., and Garske, T. (2020). Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008304"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"45","DOI":"10.11606\/s1518-8787.2022056004503","article-title":"Yellow fever vaccination before and during the covid-19 pandemic in Brazil","volume":"56","author":"Silva","year":"2022","journal-title":"Rev. Saude Publica"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak\u2014Final Report","volume":"381","author":"Casey","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(23)00809-5","article-title":"Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: Results 5 years after vaccination from a prospective cohort study","volume":"24","author":"Doshi","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.vaccine.2019.12.018","article-title":"Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis","volume":"38","author":"Nnaji","year":"2020","journal-title":"Vaccine"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMp1803433","article-title":"Fractional-Dose Yellow Fever Vaccination\u2014Advancing the Evidence Base","volume":"379","author":"Vannice","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"101635","DOI":"10.1016\/j.nmni.2025.101635","article-title":"Yellow fever in children and adolescents amid the South American outbreak, 2024\/2025","volume":"67","author":"Guevara","year":"2025","journal-title":"New Microbes New Infect"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"taz024","DOI":"10.1093\/jtm\/taz024","article-title":"Fractional-dose yellow fever vaccination: An expert review","volume":"26","author":"Roukens","year":"2019","journal-title":"J. Travel. Med."},{"key":"ref_149","first-page":"503","article-title":"A review on vector borne disease transmission: Current strategies of mosquito vector control","volume":"85","author":"Manikandan","year":"2023","journal-title":"Indian. J. Entomol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Kleinert, R.D.V., Montoya-Diaz, E., Khera, T., Welsch, K., Tegtmeyer, B., Hoehl, S., Ciesek, S., and Brown, R.J.P. (2019). Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. Viruses, 11.","DOI":"10.3390\/v11100960"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Garske, T., Van Kerkhove, M.D., Yactayo, S., Ronveaux, O., Lewis, R.F., Staples, J.E., Perea, W., and Ferguson, N.M. (2014). Yellow Fever Expert Committee. Yellow Fever in Africa: Estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001638"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1142\/S0218339016500108","article-title":"Modeling Vaccine Preventable Vector-Borne Infections: Yellow Fever as a Case Study","volume":"24","author":"Raimundo","year":"2016","journal-title":"J. Biol. Syst."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"128151","DOI":"10.1016\/j.vaccine.2025.128151","article-title":"Plaque reduction neutralization test (PRNT50) for the detection of anti-yellow fever antibodies from clinical samples","volume":"73","author":"Tyagi","year":"2025","journal-title":"Vaccine"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1016\/j.vaccine.2020.08.009","article-title":"The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines","volume":"38","author":"Condit","year":"2020","journal-title":"Vaccine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/vim.2019.0107","article-title":"Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes","volume":"33","author":"Davis","year":"2020","journal-title":"Viral Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e02294-19","DOI":"10.1128\/mBio.02294-19","article-title":"Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex","volume":"10","author":"Davis","year":"2019","journal-title":"mBio"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e01956-15","DOI":"10.1128\/mBio.01956-15","article-title":"Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses","volume":"7","author":"Meertens","year":"2016","journal-title":"mBio"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8907","DOI":"10.1038\/s41598-017-09331-w","article-title":"Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination","volume":"7","author":"Koblischke","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11538-017-0365-3","article-title":"What Controls the Acute Viral Infection Following Yellow Fever Vaccination?","volume":"80","author":"Moore","year":"2018","journal-title":"Bull. Math. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-023-00629-7","article-title":"Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models","volume":"8","author":"Muhe","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., and Archambault, D. (2019). Nanoparticle-Based Vaccines Against Respiratory Viruses. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00022"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"25151355251341662","DOI":"10.1177\/25151355251341662","article-title":"Trends in uptake and impact of thermostable vaccines in Africa","volume":"13","author":"Kitui","year":"2025","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Hansen, C.A., and Barrett, A.D.T. (2021). The Present and Future of Yellow Fever Vaccines. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090891"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"tay098","DOI":"10.1093\/jtm\/tay098","article-title":"Fractional dosing of yellow fever vaccine during shortages: Perspective from Canada","volume":"25","author":"Teitelbaum","year":"2018","journal-title":"J. Travel Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1895644","DOI":"10.1080\/21645515.2021.1895644","article-title":"Re-thinking yellow fever vaccines: Fighting old foes with new generation vaccines","volume":"18","author":"Rollier","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Yan, K., Vet, L.J., Tang, B., Hobson-Peters, J., Rawle, D.J., Le, T.T., Larcher, T., Hall, R.A., and Suhrbier, A. (2020). A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine. Vaccines, 8.","DOI":"10.3390\/vaccines8030368"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e0232224","DOI":"10.1128\/jvi.02322-24","article-title":"Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage","volume":"99","author":"Abbo","year":"2025","journal-title":"J. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"101655","DOI":"10.1016\/j.xcrm.2024.101655","article-title":"Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model","volume":"5","author":"Amanna","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Oreshkova, N., Myeni, S.K., Mishra, N., Albulescu, I.C., Dalebout, T.J., Snijder, E.J., Bredenbeek, P.J., Dallmeier, K., and Kikkert, M. (2021). A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. Vaccines, 9.","DOI":"10.3390\/vaccines9121492"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.vaccine.2018.03.091","article-title":"Inclusion of the murine IgG\u03ba signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine","volume":"36","author":"Fonseca","year":"2018","journal-title":"Vaccine"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-019-0114-8","article-title":"Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost","volume":"4","author":"Levine","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e00579-19","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation","volume":"93","author":"Pasin","year":"2019","journal-title":"J. Virol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41467-024-45806-x","article-title":"Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection","volume":"15","author":"Luppa","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Watson, A.M., and Klimstra, W.B. (2017). T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models. Viruses, 9.","DOI":"10.3390\/v9040077"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"220086","DOI":"10.1098\/rsos.220086","article-title":"Environmental determinants predicting population vulnerability to high yellow fever incidence","volume":"9","author":"Servadio","year":"2022","journal-title":"R. Soc. Open Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1016\/j.vaccine.2019.06.063","article-title":"Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources","volume":"37","author":"Adrien","year":"2019","journal-title":"Vaccine"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/S0140-6736(16)31838-4","article-title":"Fractional dosing of yellow fever vaccine to extend supply: A modelling study","volume":"388","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Gubler, D.J., Almeida, M.A.B., Cardoso, J.d.C., dos Santos, E., da Fonseca, D.F., Cruz, L.L., Faraco, F.J.C., Bercini, M.A., Vettorello, K.C., and Porto, M.A. (2014). Surveillance for Yellow Fever Virus in Non-Human Primates in Southern Brazil, 2001\u20132011: A Tool for Prioritizing Human Populations for Vaccination. PLoS Neglected Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002741"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tmaid.2018.12.008","article-title":"Epidemiological monitoring of the last outbreak of yellow fever in Brazil\u2014An outlook from Portugal","volume":"28","author":"Selemane","year":"2019","journal-title":"Travel. Med. Infect. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e220127","DOI":"10.1590\/0074-02760220127","article-title":"Fast surveillance response reveals the introduction of a new yellow fever virus sub-lineage in 2021, in Minas Gerais, Brazil","volume":"117","author":"Andrade","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"C94","DOI":"10.1016\/j.vaccine.2013.05.034","article-title":"Critical issues in implementing a national integrated all-vaccine preventable disease surveillance system","volume":"31","author":"Hyde","year":"2013","journal-title":"Vaccine"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4236\/health.2018.1010110","article-title":"Yellow Fever: A Re-Emerging Threat","volume":"10","author":"Zhao","year":"2018","journal-title":"Health"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Cruz, A.C.R., Hernandez, L.H.A., Aragao, C.F., da Paz, T.Y.B., da Silva, S.P., da Silva, F.S., de Aquino, A.A., Cereja, G., Nascimento, B., and Rosa Junior, J.W. (2023). The Importance of Entomo-Virological Investigation of Yellow Fever Virus to Strengthen Surveillance in Brazil. Trop. Med. Infect. Dis., 8.","DOI":"10.3390\/tropicalmed8060329"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42003-022-03492-9","article-title":"Yellow fever surveillance suggests zoonotic and anthroponotic emergent potential","volume":"5","author":"Real","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.onehlt.2022.100438","article-title":"Multidisciplinary approach for surveillance and risk identification of yellow fever and other arboviruses in Colombia","volume":"15","author":"Manzano","year":"2022","journal-title":"One Health"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S0007485317000700","article-title":"Tree hole mosquito species composition and relative abundances differ between urban and adjacent forest habitats in northwestern Argentina","volume":"108","author":"Mangudo","year":"2018","journal-title":"Bull. Entomol. Res."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Williams, D.T., Mackenzie, J.S., and Bingham, J. (2019). Flaviviruses. Diseases of Swine, Wiley.","DOI":"10.1002\/9781119350927.ch33"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Subramaniam, K.S., Lant, S., Goodwin, L., Grifoni, A., Weiskopf, D., and Turtle, L. (2020). Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00517"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2017.1374861","article-title":"Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines","volume":"16","author":"Zuckerman","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Cadenas-Fern\u00e1ndez, E., Barroso-Ar\u00e9valo, S., Kosowska, A., D\u00edaz-Frutos, M., Gallardo, C., Rodr\u00edguez-Bertos, A., Bosch, J., S\u00e1nchez-Vizca\u00edno, J.M., and Barasona, J.A. (2024). Challenging boundaries: Is cross-protection evaluation necessary for African swine fever vaccine development? A case of oral vaccination in wild boar. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1388812"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e180278","DOI":"10.1590\/0074-02760180278","article-title":"Yellow fever outbreak in Brazil: The puzzle of rapid viral spread and challenges for immunisation","volume":"113","author":"Possas","year":"2018","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"de Oliveira Figueiredo, P., Stoffella-Dutra, A.G., Barbosa Costa, G., Silva de Oliveira, J., Dourado Amaral, C., Duarte Santos, J., Soares Rocha, K.L., Araujo Junior, J.P., Lacerda Nogueira, M., and Zaza Borges, M.A. (2020). Re-emergence of yellow fever in Brazil during 2016\u20132019: Challenges, lessons learned, and perspectives. Viruses, 12.","DOI":"10.3390\/v12111233"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3349\/ymj.2024.0108","article-title":"Navigating the Interconnected Web of Health: A Comprehensive Review of the One Health Paradigm and Its Implications for Disease Management","volume":"66","author":"Hernandez","year":"2025","journal-title":"Yonsei Med. J."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"107275","DOI":"10.1016\/j.ijid.2024.107275","article-title":"Addressing the rise of autochthonous vector-borne diseases in a warming Europe","volume":"149","author":"Fleischmann","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41564-019-0376-y","article-title":"Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus","volume":"4","author":"Kraemer","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.nmni.2025.101663","article-title":"Beyond dengue and Oropouche: The urgent need for yellow fever preparedness in Cuba","volume":"68","year":"2025","journal-title":"New Microbes New Infect."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/QCO.0000000000000576","article-title":"Fractional-dose yellow fever vaccination: How much more can we do with less?","volume":"32","author":"Visser","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13071-024-06598-7","article-title":"Human migrations, anthropogenic changes, and insect-borne diseases in Latin America","volume":"18","author":"Wilke","year":"2025","journal-title":"Parasit. Vectors"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:45:02Z","timestamp":1767627902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":201,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010065"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010065","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}